Congestive heart failure最新文献_第10页

Dilated Cardiomyopathy in Dialysis Patients—Beneficial Effects of Carvedilol: A Double‐Blind, Placebo‐Controlled Trial 透析患者扩张性心肌病——卡维地洛的有益作用:一项双盲、安慰剂对照试验

Congestive heart failure Pub Date : 2001-05-01 DOI: 10.1111/J.1527-5299.2001.00248.X

D. Tepper

引用次数: 8

Evaluation and Management of Acutely Decompensated Chronic Heart Failure in the Emergency Department 急诊科急性失代偿期慢性心力衰竭的评估与处理

Congestive heart failure Pub Date : 2001-05-01 DOI: 10.1111/J.1527-5299.2001.00240.X

J. Kosowsky, W. Abraham, A. Storrow

{"title":"Evaluation and Management of Acutely Decompensated Chronic Heart Failure in the Emergency Department","authors":"J. Kosowsky, W. Abraham, A. Storrow","doi":"10.1111/J.1527-5299.2001.00240.X","DOIUrl":"https://doi.org/10.1111/J.1527-5299.2001.00240.X","url":null,"abstract":"A wide range of patients with symptomatic heart failure seek treatment in the emergency department. While there is no single approach to the diversity of patients with acutely decompensated heart failure, certain overarching principles apply. For patients with acute pulmonary edema or cardiogenic shock, the first priority must be rapid stabilization and treatment of reversible problems. For patients with less dramatic presentations, a more systematic search for precipitating factors may be required. Therapy, in general, is directed at reversing dyspnea and/or hypoxemia caused by pulmonary edema, improving systemic perfusion, and reducing myocardial oxygen demand. While morphine and diuretics still have their traditional roles, vasodilators and inotropic agents play an increasingly important part in the modern pharmacologic approach to decompensated heart failure in the emergency department. After evaluation and stabilization in the emergency department, most patients will require hospital admission, although a subset of low-risk patients may be appropriate for discharge to home following a period of observation. Strategies to optimize emergency department care are likely to have an impact upon patient outcomes and upon resource utilization.","PeriodicalId":10536,"journal":{"name":"Congestive heart failure","volume":"3 1","pages":"124-136"},"PeriodicalIF":0.0,"publicationDate":"2001-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80342386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Pharmacotherapy in congestive heart failure: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in congestive heart failure: do they differ in their renal effects in man? 充血性心力衰竭的药物治疗:血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在充血性心力衰竭中的作用:它们对人类肾脏的影响不同吗?

Congestive heart failure Pub Date : 2001-05-01 DOI: 10.1111/J.1527-5299.2001.00247.X

D. Sica

引用次数: 2

Thinking of heart failure as a medical emergency. 把心力衰竭当成紧急医疗事件

Congestive heart failure Pub Date : 2001-05-01 DOI: 10.1111/j.1527-5299.2001.00250.x

M. Silver

引用次数: 0

Familial dilated cardiomyopathy--more than meets the eye. 家族扩张型心肌病，比表面上看的严重。

Congestive heart failure Pub Date : 2001-05-01 DOI: 10.1111/J.1527-5299.2001.00810.X

M. Silver

引用次数: 0

Profiles of quality improvements in heart failure care. 心力衰竭护理质量改善概况。

Congestive heart failure Pub Date : 2001-05-01 DOI: 10.1111/J.1527-5299.2001.00246.X

R. J. Delaney, E. Havranek, D. Ordin, J. Taylor

引用次数: 0

Familial Dilated Cardiomyopathy 家族性扩张型心肌病

Congestive heart failure Pub Date : 2001-05-01 DOI: 10.1111/J.1527-5299.2001.00249.X

I. Pahlevan, Helen Longergan‐Thomas, S. Ande, J. Burks, E. Robin, T. Petropulos, M. Silver

引用次数: 0

Cardiac resynchronization: a novel therapy for heart failure. 心脏再同步化:心力衰竭的新疗法。

Congestive heart failure Pub Date : 2001-05-01 DOI: 10.1111/J.1527-5299.2001.00242.X

K.-l. Wong, D. Kocovic, E. Loh

{"title":"Cardiac resynchronization: a novel therapy for heart failure.","authors":"K.-l. Wong, D. Kocovic, E. Loh","doi":"10.1111/J.1527-5299.2001.00242.X","DOIUrl":"https://doi.org/10.1111/J.1527-5299.2001.00242.X","url":null,"abstract":"Despite advances in medical therapy for patients with congestive heart failure, morbidity and mortality remain high. Conduction abnormalities, such as left bundle branch block, right bundle branch block, and nonspecific conduction delay, are observed commonly in patients with dilated cardiomyopathy. In patients with heart failure, the presence of intraventricular conduction delay is associated with more severe mitral regurgitation and worsened left ventricular systolic and diastolic function, and is an independent risk factor for increased mortality. Conventional dual-chamber (right atrial and right ventricular) pacing with a short atrioventricular delay was initially introduced as therapy for patients with advanced congestive heart failure to improve diastolic dysfunction and reduce mitral regurgitation. The acute beneficial hemodynamic effects observed in early, uncontrolled studies were not confirmed in subsequent randomized, controlled studies with longer follow-up. Cardiac resynchronization with novel biventricular (left and right ventricular) pacing systems has resulted in hemodynamic and functional benefits in patients with congestive heart failure and an underlying intraventricular conduction delay. Improvements in cardiac index, systolic blood pressure, and functional class have been reported with biventricular pacing, both acutely and at more than 1 year of follow-up. These encouraging preliminary results with biventricular pacing in patients with congestive heart failure will be validated in two prospective, randomized, controlled trials, Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION). These studies are designed to evaluate the long-term efficacy of biventricular pacing in improving exercise capacity and in reducing morbidity and mortality in patients with advanced, symptomatic congestive heart failure. (c)2001 by CHF, Inc.","PeriodicalId":10536,"journal":{"name":"Congestive heart failure","volume":"16 1 1","pages":"139-144"},"PeriodicalIF":0.0,"publicationDate":"2001-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80204112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. 多非利特在充血性心力衰竭和左心室功能不全患者中的应用:安全性和对房颤的影响。丹麦多非利特心律失常和死亡率调查(DIAMOND)研究组。

Congestive heart failure Pub Date : 2001-05-01 DOI: 10.1111/J.1527-5299.2001.00243.X

M. Møller, C. Torp-Pedersen, L. Køber

{"title":"Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group.","authors":"M. Møller, C. Torp-Pedersen, L. Køber","doi":"10.1111/J.1527-5299.2001.00243.X","DOIUrl":"https://doi.org/10.1111/J.1527-5299.2001.00243.X","url":null,"abstract":"INTRODUCTION. Atrial fibrillation is a frequent cause of worsening of symptoms in patients with congestive heart failure. The drugs currently available for maintenance of sinus rhythm all have major side effects. METHODS. In 34 Danish coronary care units, 1518 patients with congestive heart failure and reduced left ventricular systolic function were randomized to receive either placebo or a new class III antiarrhythmic drug, dofetilide. The dose of dofetilide was adjusted according to the presence of atrial fibrillation, the length of the QT interval, and renal function. Patients were continuously monitored electrocardiographically for the first 3 days of the study. The primary end point was all-cause mortality and follow-up was for at least 1 year. RESULTS. In the dofetilide/placebo groups, 311/317 patients died (41%/42%). The hazard ratio for dofetilide treatment was 0.95 (95% confidence interval, 0.81-1.11). Treatment with dofetilide reduced worsening of heart failure significantly (hazard ratio, 0.75; 0.63-0.89). After 1 year, 61% of patients with atrial fibrillation at the start of the study had converted to sinus rhythm on dofetilide, vs. 33% in the placebo group. After conversion to sinus rhythm, 78%/43% of patients in the dofetilide/placebo groups remained in sinus rhythm for at least 1 year. There were 25 instances (3%) of torsade de pointes ventricular tachycardia in the dofetilide group and none in the placebo group. CONCLUSION. In patients with congestive heart failure, dofetilide can effectively convert atrial fibrillation to sinus rhythm and maintain sinus rhythm after conversion. Hospitalization for congestive heart failure is reduced. Dofetilide does not affect mortality. (c)2001 by CHF, Inc.","PeriodicalId":10536,"journal":{"name":"Congestive heart failure","volume":"61 1","pages":"146-150"},"PeriodicalIF":0.0,"publicationDate":"2001-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84907952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 52

Heart failure practice improvement effort in the outpatient setting: a health care financing administration initiative to improve the care of medicare beneficiaries with heart failure. 心力衰竭实践改进努力在门诊设置:卫生保健融资管理倡议，以改善医疗保险受益人的照顾心力衰竭。

Congestive heart failure Pub Date : 2001-03-01 DOI: 10.1111/J.1527-5299.2001.00235.X

J. Taylor, C. Mulgrew, R. Hayes, D. Ordin, E. Havranek

引用次数: 0